BioMiner: A Multi-modal System for Automated Mining of Protein-Ligand Bioactivity Data from Literature
Jiaxian Yan, Jintao Zhu, Yuhang Yang, Qi Liu, Kai Zhang, Zaixi Zhang, Xukai Liu, Boyan Zhang
Abstract
Protein-ligand bioactivity data published in the literature are essential for drug discovery, yet manual curation struggles to keep pace with rapidly growing literature. Automated bioactivity extraction remains challenging because it requires not only interpreting biochemical semantics distributed across text, tables, and figures, but also reconstructing chemically exact ligand structures (e.g., Markush structures). To address this bottleneck, we introduce BioMiner, a multi-modal extraction framework that explicitly separates bioactivity semantic interpretation from ligand structure construction. Within BioMiner, bioactivity semantics are inferred through direct reasoning, while chemical structures are resolved via a chemical-structure-grounded visual semantic reasoning paradigm, in which multi-modal large language models operate on chemically grounded visual representations to infer inter-structure relationships, and exact molecular construction is delegated to domain chemistry tools. For rigorous evaluation and method development, we further establish BioVista, a comprehensive benchmark comprising 16,457 bioactivity entries curated from 500 publications. BioMiner validates its extraction ability and provides a quantitative baseline, achieving an F1 score of 0.32 for bioactivity triplets. BioMiner's practical utility is demonstrated via three applications: (1) extracting 82,262 data from 11,683 papers to build a pre-training database that improves downstream models performance by 3.9%; (2) enabling a human-in-the-loop workflow that doubles the number of high-quality NLRP3 bioactivity data, helping 38.6% improvement over 28 QSAR models and identification of 16 hit candidates with novel scaffolds; and (3) accelerating protein-ligand complex bioactivity annotation, achieving a 5.59-fold speed increase and 5.75% accuracy improvement over manual workflows in PoseBusters dataset.
AI Impact Assessments
(3 models)Scientific Impact Assessment: BioMiner
1. Core Contribution
BioMiner addresses a genuine and significant bottleneck in drug discovery: the automated extraction of protein-ligand bioactivity data from heterogeneous scientific literature. The core intellectual contribution is the principled decoupling of bioactivity semantic interpretation from ligand structure construction, rather than attempting brittle end-to-end extraction. This is operationalized through a four-agent architecture (preprocessing, chemical structure extraction, bioactivity measurement extraction, and post-processing integration).
The most novel technical element is the Chemical-Structure-Grounded Visual Semantic Reasoning (CSG-VSR) paradigm, which delegates high-level relational reasoning (scaffold-substituent associations, coreference) to MLLMs while constraining chemical validity through deterministic domain tools (RDKit, OPSIN). This is particularly important for Markush structure enumeration—a combinatorial challenge largely unaddressed at scale in prior automated extraction work. The system converts Markush representations into specific full molecular SMILES, which is a critical capability gap in existing pipelines.
Alongside BioMiner, the authors introduce BioVista, a benchmark of 16,457 bioactivity entries from 500 publications with six evaluation tasks. This is a substantial contribution to the field's evaluation infrastructure, as no comparable benchmark existed previously.
2. Methodological Rigor
Benchmark design: BioVista is carefully constructed with strict validation/test splits (50/450 papers), inter-annotator agreement analysis (F1=0.899), model-assisted verification to reduce false negatives, and diverse journal coverage (102 journals). The held-out test design prevents overfitting to evaluation data.
Evaluation protocol: The paper provides both end-to-end and component-level evaluations, error decomposition analysis, and ablation studies (CSG-VSR removal drops F1 from 0.323 to 0.011). The comparison across 8 MLLMs (including GPT-4o-mini, Claude, Gemini, Grok) provides meaningful baselines.
Application rigor: The three downstream applications are well-designed. The pre-training experiment includes proper controls (unsupervised baseline, shuffled-label negative control), confirming that mined bioactivity signals provide genuine supervision beyond structural data augmentation. The PoseBusters annotation study employs a rigorous crossover design with 4 annotators (2 expert, 2 novice) and a blank-baseline subset to control for inter-annotator variability.
Honest reporting: The F1 of 0.32 for complete triplet extraction is modest, and the authors transparently acknowledge this, providing detailed error analysis rather than obscuring limitations. The one-shot baseline achieving F1=0.00042 contextualizes the difficulty.
Potential concerns: The 10%/90% validation/test split is acknowledged as limiting for extensive development. The OCSR model MolGlyph is trained on pseudo-labels from a closed-source model (MolParser), introducing potential noise. The NLRP3 application identifies hit candidates computationally but lacks experimental validation.
3. Potential Impact
Immediate practical impact: The three applications demonstrate concrete value:
Field impact: BioMiner could accelerate the expansion of databases like ChEMBL, BindingDB, and PDBbind, which currently rely on expensive manual curation. The HITL paradigm—where experts verify rather than perform de novo extraction—represents a practical workflow shift for database curation teams.
Broader influence: The CSG-VSR paradigm (grounding MLLM reasoning in domain-specific visual/symbolic representations) could transfer to other scientific extraction tasks requiring exact symbolic outputs (e.g., reaction extraction, materials properties, ADMET data).
Benchmark value: BioVista fills a critical gap. The six-task evaluation framework (from molecule detection to end-to-end triplet extraction) provides a structured development pathway for the community.
4. Timeliness & Relevance
This work arrives at a critical juncture. The explosive growth of MLLMs and vision-language models makes multi-modal document understanding feasible, while drug discovery increasingly depends on large-scale bioactivity data for AI-driven approaches. The gap between literature growth and manual curation capacity is widening. BioMiner directly addresses this by providing the first specialized system for this extraction task, filling a void identified in their Table S1 comparison with existing tools.
The focus on Markush structures is particularly timely—nearly half (48.7%) of structures in BioVista are Markush-derived, yet prior work largely ignored automated enumeration. As medicinal chemistry publications heavily rely on Markush representations, this capability is essential for practical deployment.
5. Strengths & Limitations
Key Strengths:
Notable Limitations:
Overall Assessment
BioMiner represents a meaningful systems-level contribution to automated scientific knowledge extraction, specifically targeting an underserved but high-value domain. While individual components build on existing tools, the integration, the CSG-VSR paradigm, and the BioVista benchmark collectively advance the field substantially. The honest acknowledgment of current limitations (F1=0.32) and the pragmatic HITL workflow design show mature engineering judgment. The paper's impact will likely be strongest through: (1) establishing BioVista as a community benchmark, (2) enabling HITL-accelerated database curation, and (3) inspiring similar grounded-reasoning approaches for other scientific extraction tasks.
Generated Apr 24, 2026
Comparison History (66)
Paper 2 likely has higher impact due to a more broadly applicable, conceptually unifying method: it bridges diffusion generative modeling with physics-based random structure search via a common sampling formulation. This advances methodology for both molecular and crystalline structure discovery, with strong real-world relevance to materials and chemistry, and demonstrates substantial efficiency gains and out-of-distribution effectiveness—key for general adoption. Paper 1 is valuable for drug-discovery data curation and provides a benchmark, but its modest extraction F1 and domain-specific pipeline suggest narrower cross-field impact than a general structure-search paradigm.
Paper 2 likely has higher scientific impact due to strong real-world applicability to drug discovery and scalable literature curation, plus the release of a sizable benchmark (BioVista) enabling broader community progress. It demonstrates end-to-end utility across multiple downstream applications with measurable gains (data scale-up, QSAR improvements, hit discovery, annotation speed/accuracy), suggesting immediate translational value and cross-field impact (NLP, vision, cheminformatics, bioinformatics). Paper 1 is novel for mechanistic interpretability in vision transformers, but its impact is more specialized and less directly tied to near-term practical outcomes.
Paper 1 likely has higher scientific impact due to strong real-world applicability in drug discovery (automating bioactivity extraction at scale), a substantial new benchmark (BioVista, 16,457 entries), and demonstrated downstream utility across multiple tasks and datasets (QSAR gains, hit discovery, annotation speedups). Its multi-modal, tool-grounded pipeline addresses a key bottleneck in biomedical data curation, with broad implications for cheminformatics, NLP, and translational science. Paper 2 is novel and timely for interpretability, but impact may be more specialized and less immediately translational.
BioMiner demonstrates immediate, measurable impact on drug discovery by solving a critical bottleneck in multi-modal bioactivity extraction. It introduces a novel framework and a massive benchmark (BioVista), proving its real-world utility by directly improving downstream QSAR models and identifying novel hit candidates. While CT Open offers a valuable benchmarking platform for future clinical forecasting challenges, BioMiner provides a completed, rigorously validated system with immediate, transformative applications in cheminformatics and pharmaceutical research.
Paper 1 addresses a critical bottleneck in drug discovery by automating multi-modal bioactivity extraction. Its concrete contributions—a new large-scale benchmark, tangible applications accelerating biological research, and the identification of novel chemical scaffolds—demonstrate immediate, highly translational scientific impact. While Paper 2 offers strong theoretical advances in AI detection, Paper 1's direct acceleration of scientific discovery across both chemistry and medicine gives it broader real-world scientific utility.
While Paper 1 offers strong theoretical advancements in AI safety, Paper 2 provides a transformative impact on actual scientific discovery. By automating the extraction of complex protein-ligand bioactivity data, BioMiner solves a major bottleneck in drug discovery. Its real-world applications—including the creation of a massive benchmark, significant improvements to downstream QSAR models, and the identification of novel hit candidates—demonstrate immediate, high-value utility in accelerating pharmaceutical research and computational chemistry.
Paper 2 has higher potential impact due to its broad, cross-domain relevance: a live, prospective evaluation platform for forecasting clinical trial outcomes with strict decontamination tackles a central reproducibility/contamination problem in modern ML. It enables ongoing community benchmarking, drives methodological innovation, and can influence both AI evaluation practices and biomedical decision-making. While Paper 1 is novel and useful for drug discovery data curation, its current extraction performance (F1=0.32) suggests maturity limitations and a narrower scope. CT Open’s timeliness and infrastructure-like role likely yield wider, longer-lasting impact.
BioMiner addresses a critical bottleneck in drug discovery—automated extraction of bioactivity data from literature—with immediate practical applications. It introduces a novel multi-modal framework, a comprehensive benchmark (BioVista), and demonstrates tangible real-world utility across three applications including improved QSAR models and hit candidate identification. While Paper 1 contributes a useful optimizer with theoretical guarantees, optimizer improvements are incremental in a saturated field. BioMiner's interdisciplinary impact spanning AI, chemistry, and drug discovery, combined with its demonstrated practical value, suggests broader and more lasting scientific impact.
BioMiner addresses a critical bottleneck in drug discovery—automated extraction of bioactivity data from literature—with a novel multi-modal framework, a comprehensive benchmark (BioVista), and three compelling real-world applications demonstrating practical utility (database construction, QSAR improvement, and annotation acceleration). Its impact spans computational biology, cheminformatics, and pharmaceutical research. While Paper 2 proposes an interesting optimizer with tunable adaptivity, optimizer papers face a crowded landscape and incremental adoption barriers. BioMiner's concrete applications, new benchmark, and direct drug discovery relevance give it broader and more immediate scientific impact.
Paper 2 likely has higher impact: it introduces an execution-grounded, long-horizon benchmark embedded in real EHR-like environments with physician-reviewed tasks across 21 specialties, addressing a timely and widely recognized bottleneck for deploying LLM agents in healthcare. Its methodological rigor (API-level verification, structured checkpoints) and broad relevance to clinical AI, agent evaluation, safety, and human-computer interaction increase cross-field influence. Paper 1 is innovative and useful for drug discovery, but its reported extraction F1 (0.32) suggests earlier-stage capability and a narrower immediate audience than an EHR benchmark likely to become a standard evaluation reference.
Paper 2 (BioMiner) has higher likely scientific impact due to broader cross-field applicability (drug discovery, cheminformatics, bioNLP/vision, database curation), clear real-world utility demonstrated via large-scale mining plus measurable downstream gains (QSAR improvements, hit discovery, annotation speed/accuracy), and a sizable new benchmark (BioVista). While Paper 1 is timely and rigorous for evaluating clinical LLM agents, it is primarily a benchmark with narrower deployment constraints (EHR access, privacy/regulation). BioMiner’s outputs directly enable new data resources and model improvements across many biomedical pipelines.
BioMiner addresses a critical bottleneck in drug discovery—automated extraction of protein-ligand bioactivity data from literature—with a comprehensive multi-modal framework, a large benchmark (BioVista), and three compelling real-world applications demonstrating practical utility (database construction, QSAR improvement, and annotation acceleration). Its direct impact on pharmaceutical research and its novel approach to multi-modal bioactivity extraction give it broader and more immediate real-world impact. Paper 2, while interesting in transferable reasoning via game self-play, addresses a more incremental advance in LLM reasoning with less demonstrated practical application.
BioMiner addresses a critical bottleneck in drug discovery—automated extraction of protein-ligand bioactivity data from literature—with a comprehensive multi-modal framework, a large benchmark (BioVista), and three compelling real-world applications demonstrating practical utility (database construction, QSAR improvement, annotation acceleration). Its direct impact on pharmaceutical research and computational biology gives it broader real-world significance. Paper 2, while novel in transferring game-based reasoning to LLMs, addresses a more incremental improvement in LLM reasoning without comparably transformative applications.
Paper 1 targets a major cross-domain bottleneck in drug discovery by extracting protein–ligand bioactivity from multimodal literature and introduces both a new system (BioMiner) and a sizable benchmark (BioVista), enabling broader community progress. It demonstrates concrete downstream benefits (data scaling, QSAR gains, hit identification, faster annotation) and has high real-world applicability across pharma, cheminformatics, NLP, and multimodal ML. Paper 2 is timely and strong but is more domain-specific (industrial RTL/EDA) and may face reproducibility barriers due to toolchain access.
BioMiner addresses a critical bottleneck in drug discovery—automated extraction of protein-ligand bioactivity data from literature—with a comprehensive multi-modal framework, a large benchmark (BioVista), and three compelling real-world applications demonstrating tangible improvements (QSAR model enhancement, hit candidate identification, annotation acceleration). Its impact spans computational biology, cheminformatics, and pharmaceutical research. Paper 2 addresses AI safety/shutdownability, which is important but more speculative; its contributions are early-stage with limited scale (simple RL environments, single LLM), and the practical relevance to advanced agent shutdown remains theoretical.
While Paper 1 offers impressive AI-driven advancements in hardware design, Paper 2 (BioMiner) promises broader cross-disciplinary impact. By automating multi-modal extraction of protein-ligand bioactivity data, it addresses a fundamental bottleneck in drug discovery. Its introduction of the BioVista benchmark and demonstration of tangible downstream applications—such as improving QSAR models, identifying novel hit candidates, and dramatically accelerating dataset construction—exhibit profound real-world utility. Unlocking vast amounts of biochemical data from existing literature has far-reaching implications for pharmacology, medicine, and bioinformatics, giving it a higher potential for widespread scientific impact.
Paper 1 likely has higher scientific impact due to a concrete, end-to-end system addressing a major drug-discovery bottleneck (scalable bioactivity curation) with clear multimodal novelty (text/table/figure + structure reconstruction), plus a sizable new benchmark (BioVista) that can anchor future work. It demonstrates multiple real-world applications with measurable downstream gains (pretraining improvements, QSAR boosts, hit discovery, annotation speedups). Paper 2 is timely and potentially important for AI safety, but the empirical scope appears narrower and impact hinges more on future scaling and adoption of DReST.
Paper 1 addresses a critical bottleneck in drug discovery with a novel multi-modal LLM approach. It demonstrates profound real-world scientific impact, including the discovery of 16 hit candidates, massive annotation speedups, and the creation of a large-scale benchmark. While Paper 2 presents a rigorous and timely framework for LLM hallucination detection, Paper 1's concrete, cross-disciplinary contributions to chemistry, biology, and AI, combined with its direct application to accelerating life-saving drug discovery, offer a broader and more transformative potential scientific impact.
Paper 2 has higher estimated impact due to a clearer core scientific contribution: a general impossibility (Non-Identifiability) theorem about enforcement-based governance in delegated agents, plus a principled alternative (IML) with provable finite detection delay and multi-setting validation. The result is broadly applicable across AI safety, control, security, and autonomous systems, and is highly timely. Paper 1 is valuable and application-rich, but its reported extraction performance (F1=0.32) suggests a less mature methodological advance and impact may be more domain-bounded to cheminformatics/biocuration.
BioMiner addresses a critical bottleneck in drug discovery—automated extraction of protein-ligand bioactivity data from literature—with demonstrated practical utility across multiple applications (database construction, QSAR improvement, hit identification). It introduces both a novel multi-modal framework and a comprehensive benchmark (BioVista). The real-world impact on pharmaceutical research, including concrete improvements in downstream model performance and identification of novel drug candidates, gives it higher scientific impact than AI-Gram, which, while creative and novel as an AI social dynamics study, has narrower practical applications and addresses a less pressing scientific need.